Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease

Neurobiology of Disease

Volumn 76, Issue , 2015, Pages 46-56

  Southwell, Amber L ^a   Franciosi, Sonia ^a   Villanueva, Erika B ^a   Xie, Yuanyun ^a   Winter, Laurie A ^b   Veeraraghavan, Janaki ^b   Jonason, Alan ^b   Felczak, Boguslaw ^a   Zhang, Weining ^a   Kovalik, Vlad ^a   Waltl, Sabine ^a   Hall, George ^a   Pouladi, Mahmoud A ^c,d   Smith, Ernest S ^b   Bowers, William J ^b   Zauderer, Maurice ^b   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VACCINEX INC   (United States)

^c AGENCY FOR SCIENCE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Huntington disease; Immunotherapy; Mouse behavior; Neuropathology; Passive immunization; Preclinical; Semaphorin; Transgenic mice

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SEMAPHORIN 4D; RECEPTOR; SEMAPHORIN; SEMAPHORIN 4D; SEMAPHORIN 4D RECEPTOR; UNCLASSIFIED DRUG; CD100 ANTIGEN; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN ATROPHY; CLIMBING; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS CALLOSUM; CORPUS STRIATUM; DRUG EFFICACY; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; FORCED SWIM TEST; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MOTOR PERFORMANCE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAROD TEST; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; BRAIN; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HUNTINGTON DISEASE; IMMUNOLOGY; METABOLISM; MOTOR ACTIVITY; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; SEMAPHORINS; SIGNAL TRANSDUCTION;

EID: 84922773047     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.01.002     Document Type: Article

References (60)

1. Adam O., Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008, 5:181-197.
2. Aziz N., et al. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008, 71:1506-1513.
3. Becanovic K., et al. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum. Mol. Genet. 2010, 19:1438-1452.
4. Bjorkqvist M., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
5. Borjabad A., Volsky D. Common transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimer's disease, and multiple sclerosis. J. Neuroimmune Pharmacol. 2012, 7:914-926.
6. Bougeret C., et al. Increased surface expression of a newly identified 150-kDa dimer early after human T lymphocyte activation. J. Immunol. 1992, 148:318-323.
7. Butters N., et al. Memory disorders associated with Huntington's disease: verbal recall, verbal recognition and procedural memory. Neuropsychologia 1985, 23:729-743.
8. Carroll J., et al. Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Mol. Neurodegener. 2011, 6:59.
9. Carroll J.B., et al. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiol. Dis. 2011, 43:257-265.
10. Caviston J.P., Holzbaur E.L.F. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009, 19:147-155.
11. Caviston J.P., et al. Huntingtin coordinates the dynein-mediated dynamic positioning of endosomes and lysosomes. Mol. Biol. Cell 2011, 22:478-492.
12. Cepeda-Prado E., et al. R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J. Neurosci. 2012, 32:6456-6467.
13. Duff K., et al. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry 2007, 62:1341-1346.
14. Ehrlich M. Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 2012, 9:270-284.
15. Ehrnhoefer D.E., et al. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nat. Rev. Drug Discov. 2011, 10:853-867.
16. Elhabazi A., et al. Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis. J. Immunol. 2001, 166:4341-4347.
17. Ellwardt E., Zipp F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp. Neurol. 2014, 262:Pt A:8-17.
18. Ernst A., et al. Neurogenesis in the striatum of the adult human brain. Cell 2014, 156:1072-1083.
19. Franciosi S., et al. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2012, 45:438-449.
20. Furuyama T., et al. Identification of a novel transmembrane semaphorin expressed on lymphocytes. J. Biol. Chem. 1996, 271:33376-33381.
21. Giraudon P., et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J. Immunol. 2004, 172:1246-1255.
22. Gray M., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
23. Graybiel A.M., et al. The basal ganglia and adaptive motor control. Science 1994, 265:1826-1831.
24. Group H.S. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006, 66.
25. Hall K.T., et al. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc. Natl. Acad. Sci. 1996, 93:11780-11785.
26. HDCRG A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
27. Hodges A., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 2006, 15:965-977.
28. Hota P., Buck M. Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions. Cell. Mol. Life Sci. 2012, 69:3765-3805.
29. Kuhn A., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007, 16:1845-1861.
30. Kumanogoh A., et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 2000, 13:621-631.
31. Kuzirian M.S., et al. The class 4 semaphorin Sema4D promotes the rapid assembly of GABAergic synapses in rodent hippocampus. J. Neurosci. 2013, 33:8961-8973.
32. Lassmann H. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. J. Neural Transm. 2011, 118:747-752.
33. Leavitt B.R., et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet. 2001, 68:313.
34. Lin C.-Y., et al. Neurovascular abnormalities in humans and mice with Huntington's disease. Exp. Neurol. 2013, 250:20-30.
35. Markianos M., et al. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia. Ann. Neurol. 2005, 57:520-525.
36. Neuwelt E.A., et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 2011, 12:169-182.
37. Okuno T., et al. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 2010, 184:1499-1506.
38. Paradis S., et al. An RNAi-based approach identifies molecules required for glutamatergic and GABAergic synapse development. Neuron 2007, 53:217-232.
39. Phan J., et al. Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum. Mol. Genet. 2009, 18:1006-1016.
40. Pouladi M.A., et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2009, 132:919-932.
41. Pridmore S.A., Adams G.C. The fertility of HD-affected individuals in Tasmania. Aust. N. Z. J. Psychiatry 1991, 25:262-264.
42. Raissi A.J., et al. Sema4D localizes to synapses and regulates GABAergic synapse development as a membrane-bound molecule in the mammalian hippocampus. Mol. Cell. Neurosci. 2013, 57:23-32.
43. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011, 10:83-98.
44. Sharp A.H., et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995, 14:1065-1074.
45. Shi W., et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T Cell activation in CD100-deficient mice. Immunity 2000, 13:633-642.
46. Slow E.J., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
47. Smith E.S., et al. SEMA4D compromises Blood-Brain Barrier and inhibits remyelination in neurodegenerative disease. Neurobiol. Dis. 2014, 73C:254-268.
48. Southwell A.L., et al. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 2009, 29:13589-13602.
49. Southwell A.L., et al. A fully humanized transgenic mouse model of Huntington disease. Hum. Mol. Genet. 2013, 22:18-34.
50. Strong T.V., et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat. Genet. 1993, 5:259-265.
51. Suzuki K., et al. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 2008, 9:17-23.
52. Swiercz J.M., et al. Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. Neuron 2002, 35:51-63.
53. Tabrizi S.J., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8:791-801.
54. Van Raamsdonk J.M., et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2005, 14:1379-1392.
55. Van Raamsdonk J.M., et al. Body weight is modulated by levels of full-length Huntingtin. Hum. Mol. Genet. 2006, 15:1513-1523.
56. Van Raamsdonk J.M., et al. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007, 26:512-520.
57. Yamaguchi W., et al. Sema4D as an inhibitory regulator in oligodendrocyte development. Mol. Cell. Neurosci. 2012, 49:290-299.
58. Yang Y.-H., et al. Plexin-B1 activates NF-kB and IL-8 to promote a pro-angiogenic response in endothelial cells. PLoS One 2011, 6:e25826.
59. Zhu L., et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc. Natl. Acad. Sci. 2007, 104:1621-1626.
60. Zuccato C., et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.